Prognosis

For cancer patients, maintaining muscle is vital to health and treatment, but staying strong is complicated

Retrieved on: 
Thursday, January 4, 2024
Patient, Cachexia, Body composition, Walking, Quality of life, Skeletal muscle, Skeleton, Myopathy, Metabolism, Movement, Prognosis, Research, Depression, Weight loss, Diet, Fatigue, Disease, Neoplasm, Exercise, Heart, Cancer, Atrophy, Anxiety, Mental health, Death, Appetite, Obesity, Gardening, Facial muscles, Inflammation, Human, Body image, Rhabdomyolysis, Dietary supplement

Nearly one-third of cancer patients die from a side-effect you’ve likely never heard of: cancer cachexia.

Key Points: 
  • Nearly one-third of cancer patients die from a side-effect you’ve likely never heard of: cancer cachexia.
  • With cachexia, a patient loses a significant amount of weight due to their disease, with considerable losses of muscle mass.

What exactly is cancer cachexia?

  • Cancer cachexia is an unintentional loss of body weight that mainly affects muscle.
  • It is diagnosed when a cancer patient loses more than five per cent of their body weight over six months.
  • Cancer cachexia is complex, and is likely caused by many factors working together.
  • Inflammation from cancer or chemotherapy, reduced appetite and food intake, or even specific interactions between a tumour and muscle could all play a role.

The impact of cachexia on patients

  • Cancer cachexia can have a significant impact on a patient’s quality of life and prognosis.
  • Patients with cachexia tend to have lower treatment tolerances than those of healthy body composition.
  • Cachexia patients report struggling with body image, loss of independence and becoming a burden to their loved ones.

Treating cachexia


Unfortunately, Canada lacks standardized options for treating patients with cancer cachexia. Research suggests that treating cachexia should use a multi-targeted approach. Nutritional interventions are essential for combating cachexia and should be started as soon as possible with consultation from a registered dietitian.

  • Exercise could be a very powerful tool to treat cachexia.
  • Studies on pharmacological compounds to treat cachexia have produced varied results, and many are still in early phase clinical trials.

Diagnosing and detecting cachexia

  • Perhaps the biggest limitation in treating cachexia is detecting it early enough to intervene.
  • Diagnosing cachexia is largely based on weight-related measures.
  • Integrating strength assessments as well as body composition scans across all points of the cancer journey could help capture the whole picture of cachexia development and progression.

Where to go from here

  • The sooner it is detected, the better chance there is to manage it.
  • Management should involve a multi-disciplinary team that can help with diet, exercise and psycho-social aspects of the condition.
  • It will likely be years before these reach the clinic, so early interventions with nutrition, exercise and regular monitoring are critical.


Meghan McCue receives funding from the Canadian Cancer Society and the Canadian Partnership Against Cancer.

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

Retrieved on: 
Thursday, January 4, 2024
Metastasis, Immunotherapy, Prognosis, FOLFIRINOX, Therapy, Standard of care, SOC, MRCP, Patient, Medical imaging

The case report, entitled “LSTA1 Potentiates Complete Response in Metastatic Gastroesophageal Adenocarcinoma,” which was co-authored by Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata, details a patient with metastatic gastroesophageal adenocarcinoma who achieved a complete response when given LSTA1, Lisata’s lead investigational product, in combination with standard of care (“SoC”) FOLFIRINOX + pembrolizumab.

Key Points: 
  • The case report, entitled “LSTA1 Potentiates Complete Response in Metastatic Gastroesophageal Adenocarcinoma,” which was co-authored by Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata, details a patient with metastatic gastroesophageal adenocarcinoma who achieved a complete response when given LSTA1, Lisata’s lead investigational product, in combination with standard of care (“SoC”) FOLFIRINOX + pembrolizumab.
  • Upon subsequent addition of LSTA1 to such SoC therapeutic regimen, the subject achieved a complete response, confirmed both radiographically and surgically.
  • As detailed in the case report, LSTA1, together with the SoC therapy, demonstrated tumor targeting and penetration-enhancing capability in this patient.
  • “We are increasingly excited to continue investigating LSTA1’s potential.”
    To read the published case report, please visit https://www.lisata.com/research-technology/publications/lsta1-potentiate...

DeciBio Forecasts the Global Clinical Oncology Biomarker Testing Market to Grow at 13% p.a., Reaching ~$12.6B in 2028 - Market Report by DeciBio Consulting LLC

Retrieved on: 
Wednesday, January 3, 2024
Science, Software, Research, Oncology, Health, Consulting, Professional Services, Technology, Geography, NGS, Medicine, Second Edition, Prognosis, PCR, Liquid biopsy, Marie Cassidy, IHC, Biomarker, Growth, Diagnosis, Therapy, Medical imaging

DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.

Key Points: 
  • DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.
  • The second edition of DeciBio’s Clinical Oncology Biomarker Testing Report takes a comprehensive look at biomarker testing for patient stratification, therapy selection, and prognosis for cancer treatment globally, including both products (kits) and services.
  • NGS, PCR, and IHC are the primary technologies utilized for clinical biomarker testing today.
  • Increased access to each of these technologies, as well as to the precision medicines requiring testing, is expected to drive significant growth of the biomarker testing market in the near-mid term.

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Retrieved on: 
Wednesday, January 3, 2024
APLM, Survival, Medicine, Prognosis, Greater, Disease, Incidence, Peking Union Medical College, Cancer, Acute myeloid leukemia, Patient, AML

This Phase 3 bridging study is being performed in China with Chinese r/r AML patients.

Key Points: 
  • This Phase 3 bridging study is being performed in China with Chinese r/r AML patients.
  • Apollomics licensed uproleselan from GlycoMimetics (Nasdaq: GLYC), including the rights to clinical development, production and commercial sales in the Greater China market (Mainland China, Hong Kong, Macau and Taiwan).
  • “AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • AML remains a major unmet medical need in China with an incidence of close to 40,000 patients every year.

Scientific Drilling acquires DynaView Data platform from Talley Energy Services

Retrieved on: 
Tuesday, January 2, 2024
Prognosis, Acquisition, 3D, WITSML, Scientific drilling, Fracture, Science, Printed circuit board

Earlier this year, the company acquired DynaView, a cutting-edge data platform that promises to revolutionize how data is managed and utilized in the industry.

Key Points: 
  • Earlier this year, the company acquired DynaView, a cutting-edge data platform that promises to revolutionize how data is managed and utilized in the industry.
  • Scientific Drilling acquires DynaView Data platform from Talley Energy Services.
  • DynaView, a state-of-the-art data platform developed by leading experts in data analytics and oil and gas technology, will empower Scientific Drilling to streamline its data operations, optimize production processes, and make more informed decisions.
  • Commenting on the acquisition, Scientific Drilling's CEO, Wes Shedd, stated, "We are thrilled to welcome DynaView into the Scientific family.

Coherus Announces U.S. Launch of LOQTORZI™

Retrieved on: 
Tuesday, January 2, 2024
DCR, Platinum, NPC, Partnership, Neoplasm, Nasopharyngeal carcinoma, Survival, ABC, Immune system, Risk, CHRS, Prognosis, McKesson Corporation, FDA, PD-1, Hope, Progression-free survival, NCCN, Research, Education, Cisplatin, HCPCS, Cancer, Sarcoma, Death, Cardinal, Patient, OS, PFS, NDC, PD-L1, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that LOQTORZI™ (toripalimab-tpzi) is now available through select specialty distributors in the United States. LOQTORZI is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor.

Key Points: 
  • In December, the NCCN committee classified LOQTORZI as a preferred category 1 treatment option in combination with gemcitabine and cisplatin.
  • LOQTORZI has demonstrated impressive clinical benefits, including PFS and OS, offering R/M NPC patients new hope for extended survival,” said Paul Reider, Chief Commercial Officer of Coherus.
  • Contact Coherus BioSciences Customer Services at 1-844-562-6004 for more information.
  • Coherus expects a product-specific, permanent J-code to be assigned to LOQTORZI in mid-2024.

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion

Retrieved on: 
Tuesday, December 19, 2023
Drug resistance, FGF, Drug discovery, Survival, Tumor microenvironment, FGFR2, FGFR1, Prognosis, Differentiable function, MHLW, Deep, Cholangiocarcinoma, Disease, FGFR, Cancer, Inflammation, Ministry, FGFR3, Proteostasis, Hypoxia, Oxidative stress, Patient, Safety, Eisai

TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, "tasurgratinib") for biliary tract cancer with FGFR2 gene fusion.

Key Points: 
  • TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, "tasurgratinib") for biliary tract cancer with FGFR2 gene fusion.
  • In Japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, (MHLW).
  • This application is based on the results of a multicenter, open-label, single-arm clinical phase II trial (Study 201) in Japan and China conducted by Eisai.
  • Study 201 enrolled patients with unresectable biliary tract cancer with FGFR2 gene fusion previously treated with gemcitabine-based combination chemotherapy.

EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study 

Retrieved on: 
Saturday, December 30, 2023
Spleen, Patient, EST, Food, TNF, Survival, Constipation, Bone marrow, BET, Prognosis, Diarrhea, Plasma, Anemia, Fatigue, Headache, Disease, Nausea, GMT, Ruxolitinib, Thrombocytopenia, Weakness, Dizziness, ASH, JAK, MorphoSys, COVID-19, Periodic breathing, European Medicines Agency, IL-6, PST, Development, Fibrosis, Cough, Dysgeusia, FACP

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points: 
  • Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
  • Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
  • Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
  • “The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

Intelligent Scopes and Mayo Clinic Collaborate to Develop AI Diagnostic Solutions in Urology for Improved Patient Outcomes

Retrieved on: 
Thursday, December 21, 2023
Image, Urology, Bladder cancer, Research, Prognosis, Cystoscopy, Mayo Clinic, Times New Roman, Artificial intelligence, Cancer, Patient, Medical device

LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology.

Key Points: 
  • LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology.
  • Combining the research capabilities and clinical expertise of Mayo Clinic, with the technology of Intelligent Scopes in image enhancement and expertise in development of precision AI diagnostic tools, this collaboration aims to deliver software tools that aid urologists in the detection, surgery, and post-treatment surveillance.
  • This digital healthcare collaboration intends to deliver reliable AI diagnostic solutions that can be used by urologists globally for accurate detection of bladder cancer and to minimize unnecessary interventions thereby improving patient outcomes.
  • Early and accurate detection has the potential to significantly improve the prognosis for patients and reduce costs to providers and payors.

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Retrieved on: 
Tuesday, December 19, 2023
Prognosis, Galapagos NV, Euronext, Patient, B-cell maturation antigen, Multiple myeloma, Safety, Quality of life, BCMA

This is Galapagos’ third oncology CAR-T program in clinical development.

Key Points: 
  • This is Galapagos’ third oncology CAR-T program in clinical development.
  • GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate, administered as an intravenous infusion of a fresh product in a single fixed dose, at point-of-care.
  • “Patients living with relapsed/refractory multiple myeloma have a very poor prognosis and a significant high unmet medical need for novel treatment options.
  • “We are very pleased that the first patient with rrMM in PAPILIO-1 has been dosed with our BCMA CAR-T candidate, GLPG5301.